Please check out this most recent podcast, where I talk with MaryBeth Gilliam from Outperform Cancer about the importance of genetic testing and how AI is transforming cancer . podcasts.apple.com/us/podcast/out…
English
Nathan Fowler
631 posts
Nathan Fowler
@DrNathanFowler
CMO-BostonGene; Pres-Halo House Foundation; ex Prof of Med-MD Anderson. Constantly searching for innovative ways to battle cancer and improve patients lives
Houston, TX Katılım Mayıs 2016
404 Takip Edilen2.9K Takipçiler
Nathan Fowler retweetledi
BostonGene to Present Seven Studies Unveiling Novel AI-Driven Breast Cancer Breakthroughs at SABCS 2025 dlvr.it/TPhwBc
English
Beating cancer requires more than just therapy. In the middle of a campaign to double the size of Halo House. Check out our recent campaign video!
youtube.com/watch?v=8QrehD…
YouTube
English
RNA data in cancer is complex, tough to interpret, and often poorly understood. Today we published a new AI tool to help define "bad". AI is changing how we will use technology to better understand cancer. rdcu.be/eSSPN
English
thanks everyone for your support. halohousefoundation.org/_api/media-sha…
English
Excellente presentation by Ranjit Nair @MDAndersonNews @LNastoupilMD @ChrisRFlowersMD showcasing the very promising phase 1 study results of TNB-486 in R/R FL.
Lugano, Switzerland 🇨🇭 English
@DrSwami_Iyer @MDAndersonNews @LNastoupilMD @ChrisRFlowersMD @WomenInLymphoma @Lymphoma_Doc @lymphomahub @PallawiTorkaMD @majorajay @Eddie_Cliff @DrAnasYounes @doctorpemm Great job. Our rising star.
English
Nathan Fowler retweetledi
He’s got some truly incredible content but this might be my favorite @DGlaucomflecken tweet of all time
Dr. Glaucomflecken@DGlaucomflecken
Since the cardiac arrest, every time my kids do something sweet like climb into my lap to watch a campfire, I feel this relief that I’m still here to experience that moment. It feels happy and sad, if that makes sense. Not sure how long that feeling will last, maybe forever.
English
Nathan Fowler retweetledi
In an interim analysis of the pivotal phase 2 ELARA trial, anti-CD19 #CARTcells produced a high rate of complete responses with a manageable safety profile in adults with r/r #FollicularLymphoma #lymsm #immunotherapy @DrNathanFowler @NovartisCancer nature.com/articles/s4159…
English
Nathan Fowler retweetledi
The #FDA has given accelerated approval to #tisagenlecleucel for treatment of adult patients with relapsed or refractory #follicular #lymphoma (#FL). Read about the #ELARA trial, published in @NatureMedicine by @DrNathanFowler that led to the approval: oncdata.com/news/accelerat…
English
English
12 years ago I was at #ASCO22 to present some posters from my time at @MDAndersonNews, guided by my mentors @bpromd @DrNathanFowler and @lefayad.
This year I come back as one of the authors of the SHINE trial, Just presented by @michaelwangmd.
What an improbable journey...
English
@MediHumdani If pt is in CR, I would agree with going to commercial CAR-T. Biopsy would be nice, but unclear if CD19 status should affect next steps..as Lonca could cause dynamic (and temporary) expression change. Happy to talk off line.
English
Nathan Fowler retweetledi
See what our experts Drs. Fowler (@DrNathanFowler), Nancy L. Bartlett, & Patel (@KrishPatelMD) have to say about targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of #FollicularLymphoma. #ASH21 bit.ly/36nxmlf #meded #lymsm
English
Nathan Fowler retweetledi
Congratulations @DrNathanFowler et al on these important data. Love to see a trial vs mosun
Toby Eyre@tobyeyre82
Tisagenlecleucel in R/R #FL ELARA trial in @NatureMedicine 2+ prior lines median 4 (2-13) N=97 POD24 63% Double ref 68% CR 69% ORR 86% CRS 48.5% G≥3 0% (Lee scale) ICANS 4.1% G≥3 1% 12m PFS 67% Highly active in R/R high risk FL including refractory and POD24 pts #lymsm
Perth, Western Australia 🇦🇺 English
@AshAlizadeh So sorry to hear. He was a great person and colleague. Always kind and insightful.
English
I'm brokenhearted by the loss of my friend & colleague, Steve Coutre, a giant in #hematology. Steve trained & mentored me & inspired many to love & pursue #hematology. He touched the lives of many patients & peers as a clinician, scientist, & leader. My thoughts are w/ his family
English
Phenomenal. Congrats Dr Jabbour and team!
Hagop Kantarjian,MD@DrHKantarjian
A combination of 2 targeted drugs, ponatinib+ blinatumomab, WITHOUT ANY CHEMOTHERAPY, results in 100% complete response rate, 85% complete molecular remission rate in newly diagnosed pts w/ Ph-positive #ALL. @MDAndersonNews study led by @NicholasShortMD & Jabbour #leusm #ASCO21
English
Very cool summary of our recent paper in Cancer Cell. Major impact!
Cancer Cell@Cancer_Cell
A tumor “personality” test to guide therapeutic decision making dlvr.it/S1zzR5
English
As one example (of many), we treat different patients w/DH/TH DLBCL with R-EPOCH, R-CHOP, and mini-R-CHOP & sometimes switch in the middle based on how things are going & in discussion w/the patient/family - complex & data have limits in guiding-new data influence but not resolve
John P. Leonard, MD@JohnPLeonardMD
The shared decision making that goes into good cancer care in the setting of (always present) limitations of available data does not fit well into a tweet…nor should absolutes…..
English
Nathan Fowler retweetledi
